Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Borderline resectable pancreatic ductal adenocarcinoma
Data

Cancers·Borderline resectable pancreatic ductal adenocarcinoma

DataBorderline resectable pancreatic ductal adenocarcinoma

Back to the Borderline resectable pancreatic ductal adenocarcinoma hub →103 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

103

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Pancreatic acinar cell carcinoma
Shares Richard Schulick, PDAC organoid pharmacotyping, Eileen M. O'Reilly, Whipple procedure (pancreaticoduodenectomy) and the tags subtype-page, gastrointestinal.
Cancer
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Shares Richard Schulick, Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting), Marc G. Besselink, Resectable, borderline resectable and unresectable and the tags subtype-page, gastrointestinal.
Cancer
KRAS wild-type pancreatic ductal adenocarcinoma
Shares NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Eileen M. O'Reilly, Pancreatic cancer (KEGG map), KRAS G12C-mutant pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Shares Eileen M. O'Reilly, PRODIGE 24 / CCTG PA6, Whipple procedure (pancreaticoduodenectomy), KRAS G12C-mutant pancreatic ductal adenocarcinoma and the tags subtype-page, gastrointestinal.
Cancer
Pancreatoblastoma
Shares Whipple procedure (pancreaticoduodenectomy), Resection margins (R0 / R1 / R2), Pancreatic cancer (KEGG map), CT (computed tomography) and the tags subtype-page, gastrointestinal.
Cancer
Localised small bowel adenocarcinoma (stage I to III, resected)
Shares Whipple procedure (pancreaticoduodenectomy), CT (computed tomography), KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Localised anal squamous cell carcinoma (stage I to III)
Shares Chemoradiation (chemoradiotherapy, CRT), Robotic & minimally invasive surgery, Capecitabine, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares CT (computed tomography), KRAS, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.

technologies

Biliary stenting and drainage CT (computed tomography)Cytotoxic chemotherapy Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)KRAS & RAS inhibitors Liquid biopsy (ctDNA)MR-guided adaptive radiotherapy PDAC organoid pharmacotyping Personalised neoantigen (mRNA) vaccines Platinum agents Robotic & minimally invasive surgery SBRT / SABR (stereotactic radiotherapy)Topoisomerase-I inhibitors (and ADC payloads)

targets

BRCA1 / BRCA2 (HRD)KRAS

drugs

Phase 2Personalised mRNA neoantigen vaccine

Autogene cevumeran

ApprovedOral fluoropyrimidine prodrug (antimetabolite)

Capecitabine · Xeloda

ApprovedSmall-molecule pan-RAS(ON) inhibitor

Daraxonrasib · Rasonque

ApprovedCytotoxic regimen

FOLFIRINOX / mFOLFIRINOX

ApprovedNucleoside analogue (deoxycytidine)

Gemcitabine · Gemzar / Infugem

ApprovedCytotoxic regimen

Gemcitabine + nab-paclitaxel · Gemzar + Abraxane

ApprovedCytotoxic regimen

NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen

companies

BioNTech Dutch Pancreatic Cancer Group Eli Lilly (incl. Loxo)Ipsen Revolution Medicines Roche / Genentech

pathways

Fibroblast activation, desmoplasia & matrix stiffness Pancreatic cancer (KEGG map)

terms

CA 19-9 Chemoradiation (chemoradiotherapy, CRT)Circulating tumour DNA (ctDNA)Locally advanced and locoregional disease Neoadjuvant / adjuvant / perioperative Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)Pancreatic cancer trials open today (registry snapshot and UK sites)R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)Resectable, borderline resectable and unresectable Resection margins (R0 / R1 / R2)Stereotactic body radiotherapy (SBRT / SABR)Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)Whipple procedure (pancreaticoduodenectomy)

trials

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.Alliance A021501 Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer ESPAC-5 Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101 Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)PREOPANC-1 PREOPANC-2 Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma PRODIGE 24 / CCTG PA6 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas PULSAR in Systemic Therapy for Pancreatic Cancer Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer

roadmaps

Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question

ideas

Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed Grow each trial patient's tumour as organoids to decide which platform arm opens next RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable

people

Albert C. Koong Eileen M. O'Reilly Jürgen Weitz Marc G. Besselink Paula Ghaneh Richard Schulick Theodore S. Hong

key papers

Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-22 · Jude Gomila · Content wave 3, pancreatic family · diff · file

Wikipedia

Pancreatic cancer

Sources & links

Wikipedia
NCCN Guidelines: Pancreatic Adenocarcinoma

subtype-page gastrointestinal

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Borderline resectable pancreatic ductal adenocarcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/borderline-resectable-pdac/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id borderline-resectable-pdac.

WebMCP tools registered on this page: onco_search, onco_get_entity.